ReviewBMC neurology2026
Clinical and neuroradiological findings in patients with Anti-AMPAR encephalitis: associations with outcomes.
Review in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundEncephalitis associated with antibodies against the α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic acid receptor (AMPAR) is an extremely rare type of antibody-mediated encephalitis. Its clinical phenotype and neuroradiological characteristics remain incompletely described.
methodsWe present four cases of anti-AMPAR encephalitis, and a comprehensive literature review highlighted the diverse clinical experiences, with specific attention to the clinical and radiographic characteristics of anti-AMPAR encephalitis, as well as the association between clinical, neuroradiological presentations and outcomes.
resultsA total of 89 patients with anti-AMPAR encephalitis were included in this review. Clinical presentations at the onset of anti-AMPAR encephalitis were diverse, including behavioral, cognitive, motor, and sensory manifestations. Neuroradiological findings cannot be restricted to the limbic system. They may spread to unexpected sites, like basal ganglia, cerebellum, cerebral cortex regions, and even diffuse hyperintensities, or patient may have completely normal brain magnetic resonance imaging (MRI). Fisher’s exact test showed that there was non-significant difference in the clinical symptoms and outcomes among different MRI presentations.Logistic regression analysis showed no significant correlations between clinical, neuroradiological findings and unfavorable outcome.
conclusionAnti-AMPAR encephalitis mainly presents as limbic encephalitis, and most of the patients had positive brain MRI results. The range of hyperintensity on MRI may not be directly associated with patients’ clinical symptoms and outcomes. For the expanding clinical profile of encephalitis associated with antibodies against AMPAR, careful databasing of new cases will facilitate more definitive study in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.